Neumora Therapeutics Overview
Neumora Therapeutics (NMRA) has a ROE of -477.87%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-477.87%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Neumora Therapeutics (NMRA) currently reports a ROE of -477.87%. That is below the sector sector average of -5.68%. Use the charts on this page to explore Neumora Therapeutics's ROE history and peer comparisons.
Neumora Therapeutics's ROE of -477.87% is lower than the its sector sector average of -5.68%. That is roughly 8309.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Neumora Therapeutics's current -477.87% should be judged against industry norms (sector average: -5.68%) and against NMRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -477.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for Neumora Therapeutics, and consider following NMRA for alerts when major investors trade the stock.
